NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Monday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NeuroMetrix stock opened at $4.05 on Monday. The firm’s fifty day moving average price is $3.59 and its 200-day moving average price is $3.84. The stock has a market cap of $8.14 million, a P/E ratio of -0.64 and a beta of 2.28. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $6.29.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The business had revenue of $0.77 million for the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.